0001209191-19-044214.txt : 20190802
0001209191-19-044214.hdr.sgml : 20190802
20190802160424
ACCESSION NUMBER: 0001209191-19-044214
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190731
FILED AS OF DATE: 20190802
DATE AS OF CHANGE: 20190802
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lemkey John G
CENTRAL INDEX KEY: 0001495904
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38318
FILM NUMBER: 19995988
MAIL ADDRESS:
STREET 1: 4401 EASTGATE MALL
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Odonate Therapeutics, Inc.
CENTRAL INDEX KEY: 0001717452
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 822493065
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4747 EXECUTIVE DRIVE
STREET 2: SUITE 510
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-200-3830
MAIL ADDRESS:
STREET 1: 4747 EXECUTIVE DRIVE
STREET 2: SUITE 510
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Odonate Therapeutics, Inc
DATE OF NAME CHANGE: 20171207
FORMER COMPANY:
FORMER CONFORMED NAME: Odonate Therapeutics, LLC
DATE OF NAME CHANGE: 20170919
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-07-31
0
0001717452
Odonate Therapeutics, Inc.
ODT
0001495904
Lemkey John G
C/O ODONATE THERAPEUTICS, INC.
4747 EXECUTIVE DRIVE, SUITE 510
SAN DIEGO
CA
92121
0
1
0
0
Chief Operating Officer
Common Stock
2019-07-31
4
A
0
33
34.64
A
1783
D
Common Stock
14075269
I
By LP
Employee Stock Option (Right to Buy)
40.75
2019-07-31
4
A
0
33
0.00
A
2029-07-31
Common Stock
33
33
D
These shares were acquired on 07/31/2019 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Tang Capital Management, LLC ("TCM") is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Mr. Lemkey has a pecuniary interest in a portion of the shares beneficially held by TCP.
The stock options vest as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date.
/s/ John Lemkey
2019-08-02